{"url_path":"/sec/enta/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 OTHER INFORMATION","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1177648/0001193125-26-220572-index.html","accession_number":"0001193125-26-220572","cik":"0001177648","ticker":"ENTA","issuer_name":"ENANTA PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1177648/0001193125-26-220572-index.html","primary_entity_key":"0001177648","primary_entity_name":"ENANTA PHARMACEUTICALS INC"},"word_count":57,"has_tables":true,"body_markdown":"ITEM 5. OTHER INFORMATION\n\nRule 10b5-1 Trading Arrangements. During the three months ended March 31, 2026, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-rule 10b5-1 trading arrangement,” as each term is defined in item 408(a) of Regulation S-K.\n\n28"}